NCT02978781 - A Study to Evaluate SAGE-217 in Participants With Essential Tremor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 24, 2017

Primary Completion Date

November 22, 2017

Study Completion Date

December 5, 2017

Conditions

Essential Tremor

Interventions

DRUG

SAGE-217

SAGE-217 Oral Solution

DRUG

SAGE-217

SAGE-217 Capsules

DRUG

Placebo

SAGE-217 matching placebo capsules

Trial Locations (26)

27612

Sage Investigational Site, Raleigh

30030

Sage Investigational Site, Decatur

30331

Sage Investigational Site, Atlanta

32174

Sage Investigational Site, Ormond Beach

32720

Sage Investigational Site, DeLand

32806

Sage Investigational Site, Orlando

33319

Sage Investigational Site, Lauderdale Lakes

33612

Sage Investigational Site, Tampa

33713

Sage Investigational Site, St. Petersburg

33756

Sage Investigational Site, Clearwater

36207

Sage Investigational Site, Anniston

37232

Sage Investigational Site, Nashville

45212

Sage Investigational Site, Cincinnati

45417

Sage Investigational Site, Dayton

60612

Sage Investigational Site, Chicago

61801

Sage Investigational Site, Urbana

63141

Sage Investigational Site, St Louis

65802

Sage Investigational Site, Springfield

72211

Sage Investigational Site, Little Rock

72758

Sage Investigational Site, Rogers

76104

Sage Investigational Site, Fort Worth

80113

Sage Investigational Site, Englewood

90703

Sage Investigational Site, Cerritos

92056

Sage Investigational Site, Oceanside

92103

Sage Investigational Site, San Diego

92708

Sage Investigational Site, Fountain Valley